Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Castle Biosciences Inc (NQ: CSTL ) 19.92 +0.98 (+5.17%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 418,421 Open 18.87 Bid (Size) 19.56 (1) Ask (Size) 20.25 (2) Prev. Close 18.94 Today's Range 18.70 - 20.23 52wk Range 12.07 - 25.91 Shares Outstanding 25,167,365 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Castle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024 July 15, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences Honored with Top Workplaces Awards July 11, 2024 From Castle Biosciences Inc. Via Business Wire Performance YTD -9.29% -9.29% 1 Month -5.46% -5.46% 3 Month +1.58% +1.58% 6 Month +0.66% +0.66% 1 Year +19.07% +19.07% More News Read More Top 5 Health Care Stocks That May Explode In July July 08, 2024 Via Benzinga Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session July 05, 2024 Via Benzinga Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher® Test June 24, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 20, 2024 From Castle Biosciences Inc. Via Business Wire 12 Health Care Stocks Moving In Wednesday's After-Market Session June 19, 2024 Via Benzinga Castle Biosciences’ Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner June 14, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance May 30, 2024 From Castle Biosciences Inc. Via Business Wire New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis May 29, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference May 15, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024 May 14, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution” May 10, 2024 From Castle Biosciences Inc. Via Business Wire Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result May 08, 2024 From Castle Biosciences Inc. Via Business Wire DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck May 03, 2024 From Castle Biosciences Inc. Via Business Wire CSTL Stock Earnings: Castle Biosciences Beats EPS, Beats Revenue for Q1 2024 May 02, 2024 Via InvestorPlace Castle Biosciences Reports First Quarter 2024 Results May 02, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT Melanoma April 30, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024 April 11, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations April 10, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year April 10, 2024 From Castle Biosciences Inc. Via Business Wire Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer April 04, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference April 02, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences Announces Updates to its Board of Directors March 27, 2024 From Castle Biosciences Inc. Via Business Wire Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year March 25, 2024 From Castle Biosciences Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.